Shares of 89bio ripped to a record on Thursday after Roche agreed to acquire the biotech for up to 3.5 billion, adding a late-stage MASH therapy to its expanding metabolic portfolio. 89bio jumped as much as 86 percent intraday to 15.06 and closed near 14.96, well above Roche’s 14.50 cash tender, as investors priced in some probability of contingent payouts tied to clinical milestones.
Roche will launch a tender offer at 14.50 per share, a 52 percent premium to 89bio’s 60-day volume weighted average price, with an additional non-tradable contingent value right worth up to 6.00 per share if specified milestones are met. That puts the upfront equity value around 2.4 billion at closing and a headline deal value up to 3.5 billion. The structure splits risk: sellers get cash today, while Roche ties the top-end price to the performance of 89bio’s lead asset, pegozafermin. In a statement, Roche said the acquisition advances its strategy in cardiovascular, renal and metabolic diseases, specifically targeting overweight and obesity-related conditions, including metabolic dysfunction-associated steatohepatitis, or MASH. The companies expect to close in the fourth quarter of 2025, subject to customary conditions. The CVR introduces a meaningful range of outcomes for holders. If pegozafermin hits development and regulatory hurdles, the full 6.00 could pay out; if timelines slip or data stumble, the CVR could expire worthless. That binary risk is why shares climbed above the cash offer but not close to the maximum package.
For Roche, 89bio plugs directly into a therapeutic area where it has been leaning in. The Swiss drugmaker has been rebuilding exposure to metabolic disease, most visibly with last year’s Carmot deal to acquire obesity drug candidates. With MASH now recognized as a high-prevalence liver condition linked to obesity and diabetes, Roche is buying optionality in a market that has moved from promise to product with the recent approval of the first NASH therapy. Pegozafermin is an FGF21 analog aiming to reduce liver fat and improve fibrosis. In Phase IIb data from the ENLIVEN study, 27 percent of patients on the 44-mg twice-weekly dose achieved at least a one-stage improvement in fibrosis without worsening of MASH, versus 7 percent for placebo. While cross-trial comparisons are fraught, those signals put FGF21 biology in the conversation alongside thyroid hormone receptor beta agonists and incretin-based strategies for liver disease. Roche gets a late-stage asset and a clinical team that has navigated liver disease endpoints, while avoiding the full cost of Phase 3 and commercialization risk via the CVR.
The tape told a clear story. With 89bio stock around 14.96 into the close, arbitrage desks and event-driven funds effectively assigned about 46 cents of value to the CVR, after accounting for deal risk and time value. On a simple basis, that implies a low-single-digit probability of the full 6.00 paying out, or a higher probability of partial milestones. The spread will move as investors refine their models around pegozafermin’s trial design, regulatory pathway, and the timing of any interim looks. Tender deals also bring borrow dynamics and proration risks that can widen spreads. Still, the immediate reaction — shares vaulting above the base cash — suggests the market believes the milestones are neither remote nor purely cosmetic. That pricing could tighten if Roche files details on the CVR triggers, especially if any near-term readouts are in play that would accelerate a partial payout.
The core question for valuation is how quickly pegozafermin can read out pivotal data and secure a filing in MASH. The Phase IIb ENLIVEN results provided a proof-of-concept signal on fibrosis improvement without worsening MASH, an endpoint that regulators have embraced as meaningful. The late-stage program will need to replicate and extend those findings in larger populations and across dosing regimens that balance efficacy with tolerability. Safety and long-term outcomes remain under scrutiny given the chronic nature of MASH therapy. If pegozafermin’s Phase 3 design incorporates histology-based endpoints aligned with current approval standards, interim histology readouts could serve as CVR triggers, depending on how Roche structured the milestones. Watch for clarity on enrollment timelines, geographic mix, and any adaptive features that could pull forward decision points. The faster Roche can de-risk the program, the tighter the CVR discount should get.
Roche is stepping into a competitive and fluid market. The first approval in NASH set a regulatory template and sparked renewed interest in complementary mechanisms that target liver fat, inflammation, and fibrosis. Incretin-based drugs from Novo Nordisk and Eli Lilly continue to reshape obesity care, with ripple effects across metabolic comorbidities, including liver disease. Other FGF21 programs, such as those at Akero, offer direct comps to 89bio on efficacy and dosing cadence. That makes this deal a read-across moment: if Roche is willing to pay up to 3.5 billion for an FGF21 asset with Phase IIb data, peers with similar biology or adjacent mechanisms may see increased inbound interest. Expect investors to cycle through the space looking for who fits which buyer’s gap. The bid also underscores a pragmatic shift in big pharma dealmaking in metabolism: pay modest cash today, reserve larger checks for assets that hit pre-agreed proof points.
Antitrust scrutiny should be limited here. The MASH market is nascent, and 89bio’s revenue base is pre-commercial. The heavier lift is operational: aligning clinical, regulatory, and CMC workstreams to hit Roche’s internal timelines. Integrating a lean biotech into a large-cap organization can slow decision cycles; Roche will need to preserve the speed that got 89bio through ENLIVEN while layering in big-company resources for Phase 3 and manufacturing scale-up. The tender structure should speed closing once regulatory and shareholder thresholds are met, but CVR mechanics will keep both parties engaged post-close. On guidance, Roche has not flagged material near-term P and L impact from the deal. Investors will look for pipeline updates that sequence pegozafermin milestones alongside obesity assets acquired from Carmot, framing a broader CVRM narrative to offset erosion elsewhere in the portfolio.
For 89bio holders, the next catalyst is the tender offer launch and the detailed CVR agreement. The stock trading above 14.50 suggests some holders will ride the CVR rather than sell into the market, especially those already underwriting the clinical path. Event funds will model expected value scenarios for the CVR, discounting for duration and risk, and adjust positions as new trial and regulatory details emerge. For Roche shareholders, the strategic logic is straightforward: deepen exposure to metabolic and liver disease where patient need and payer willingness to reimburse are rising, while capping top-of-market risk via contingent consideration. The real test will come with Phase 3 data. If pegozafermin can deliver reproducible fibrosis improvements with a manageable safety profile and a dosing schedule that holds up in the real world, Roche will have bought a cornerstone liver asset at a price that scales with success. If not, it paid an industry-standard premium for optionality and keeps the balance sheet flexible for the next move.
